YC-1 targeting of hypoxia-inducible factor-1α reduces RGC-5 cell viability and inhibits cell proliferation

Molecular Vision

Volumn 18, Issue , 2012, Pages 1594-1603

  Tsui, Leo ^a   Fong, Tsorng Harn ^a,b   Wang, I Jong ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIFICIGUAT;

APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; PRIORITY JOURNAL; RETINA GANGLION CELL;

ANTIBODIES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; KI-67 ANTIGEN; RETINAL GANGLION CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84863322445     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Isenmann S, Kretz A, Cellerino A. Molecular determinants of retinal ganglion cell development, survival, and regeneration. Prog Retin Eye Res 2003; 22:483-543. [PMID: 12742393]
2. Kaur C, Foulds WS, Ling EA. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol 2008; 2:879-89. [PMID: 19668442]
3. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995; 36:774-86. [PMID: 7706025]
4. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol 1997; 115:1031-5. [PMID: 9258226]
5. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci 2004; 45:2760-6. [PMID: 15277502]
6. Duncan RS, Xin H, Goad DL, Chapman KD, Koulen P. Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, Nlinoleoylethanolamine. Clin Ophthalmol 2011; 5:543-8. [PMID: 21573043]
7. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res 1997; 37:3483-93. [PMID: 9425525]
8. Qu J, Wang D, Grosskreutz CL. Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res 2010; 91:48-53. [PMID: 20394744]
9. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol 1997; 115:497-503. [PMID: 9109759]
10. Morgan JE, Jeffery G, Foss AJ. Axon deviation in the human lamina cribrosa. Br J Ophthalmol 1998; 82:680-3. [PMID: 9797672]
11. Findl O, Strenn K, Wolzt M, Menapace R, Vass C, Eichler HG, Schmetterer L. Effects of changes in intraocular pressure on human ocular haemodynamics. Curr Eye Res 1997; 16:1024-9. [PMID: 9330854]
12. Pillunat LE, Anderson DR, Knighton RW, Joos KM, Feuer WJ. Autoregulation of human optic nerve head circulation in response to increased intraocular pressure. Exp Eye Res 1997; 64:737-44. [PMID: 9245904]
13. Kaur C, Sivakumar V, Foulds WS. Early response of neurons and glial cells to hypoxia in the retina. Invest Ophthalmol Vis Sci 2006; 47:1126-41. [PMID: 16505051]
14. Wang GL, Semenza GL. General involvement of hypoxiainducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90:4304-8. [PMID: 8387214]
15. Yeo EJ, Chun YS, Park JW. New anticancer strategies targeting HIF-1. Biochem Pharmacol 2004; 68:1061-9. [PMID: 15313402]
16. Correia SC, Moreira PI. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration? J Neurochem 2010; 112:1-12. [PMID: 19845827]
17. Li SY, Lo AC. Lutein protects RGC-5 cells against hypoxia and oxidative stress. Int J Mol Sci 2010; 11:2109-17. [PMID: 20559505]
18. Tulsawani R, Kelly LS, Fatma N, Chhunchha B, Kubo E, Kumar A, Singh DP. Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage. BMC Neurosci 2010; 11:125. [PMID: 20923568]
19. Zhu X, Zhou W, Cui Y, Zhu L, Li J, Feng X, Shao B, Qi H, Zheng J, Wang H, Chen H. Pilocarpine protects cobalt chloride-induced apoptosis of RGC-5 cells: involvement of muscarinic receptors and HIF-1 alpha pathway. Cell Mol Neurobiol 2010; 30:427-35. [PMID: 19816768]
20. Men J, Zhang X, Yang Y, Gao D. An AD-related neuroprotector rescues transformed rat retinal ganglion cells from CoCl(2)-induced apoptosis. J Mol Neurosci 2012; 47:144-9. [PMID: 22222604]
21. Zhu X, Zhou W, Cui Y, Zhu L, Li J, Xia Z, Shao B, Wang H, Chen H. Muscarinic activation attenuates abnormal processing of beta-amyloid precursor protein induced by cobalt chloride-mimetic hypoxia in retinal ganglion cells. Biochem Biophys Res Commun 2009; 384:110-3. [PMID: 19393223]
22. Whitlock NA, Agarwal N, Ma JX, Crosson CE. Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest Ophthalmol Vis Sci 2005; 46:1092-8. [PMID: 15728570]
23. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994; 84:4226-33. [PMID: 7527671]
24. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, Park JW. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001; 61:947-54. [PMID: 11286986]
25. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95:516-25. [PMID: 12671019]
26. Kim HL, Yeo EJ, Chun YS, Park JW. A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. Int J Oncol 2006; 29:255-60. [PMID: 16773207]
27. Lau CK, Yang ZF, Lam CT, Tam KH, Poon RT, Fan ST. Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun 2006; 348:1443-8. [PMID: 16919599]
28. Li SH, Shin DH, Chun YS, Lee MK, Kim MS, Park JW. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIHdependent p300 dissociation from HIF-1{alpha}. Mol Cancer Ther 2008; 7:3729-38. [PMID: 19074848]
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63. [PMID: 6606682]
30. Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 1993; 303:474-82. [PMID: 8390225]
31. Marshall NJ, Goodwin CJ, Holt SJ. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. Growth Regul 1995; 5:69-84. [PMID: 7627094]
32. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184:39-51. [PMID: 7622868]
33. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182:311-22. [PMID: 10653597]
34. Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol 2010; 28:237-45. [PMID: 20346526]
35. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004; 19:176-82. [PMID: 15304631]
36. Siddiq A, Aminova LR, Ratan RR. Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection. Front Biosci 2008; 13:2875-87. [PMID: 17981760]
37. Zhang Z, Yan J, Chang Y. ShiDu Yan S, Shi H. Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr Med Chem 2011; 18:4335-43. [PMID: 21861815]
38. Tulis DA, Bohl Masters KS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ, Durante W, West JL, Schafer AI. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun 2002; 291:1014-21. [PMID: 11866467]
39. Hsu HK, Juan SH, Ho PY, Liang YC, Lin CH, Teng CM, Lee WS. YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem Pharmacol 2003; 66:263-71. [PMID: 12826268]
40. Wu CH, Chang WC, Chang GY, Kuo SC, Teng CM. The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. J Pharmacol Sci 2004; 94:252-60. [PMID: 15037810]
41. Wang SW, Pan SL, Guh JH, Chen HL, Huang DM, Chang YL, Kuo SC, Lee FY, Teng CM. YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 2005; 312:917-25. [PMID: 15525795]
42. Chiang WC, Teng CM, Lin SL, Chen YM, Tsai TJ, Hsieh BS. YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. Eur J Pharmacol 2005; 517:1-10. [PMID: 15950964]
43. Yeo EJ, Ryu JH, Chun YS, Cho YS, Jang IJ, Cho H, Kim J, Kim MS, Park JW. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res 2006; 66:6345-52. [PMID: 16778212]
44. Linsenmeier RA, Braun RD, McRipley MA, Padnick LB, Ahmed J, Hatchell DL, McLeod DS, Lutty GA. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci 1998; 39:1647-57. [PMID: 9699554]
45. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol 1999; 43:S43-50. [PMID: 10416746]
46. Costa VP, Harris A, Stefansson E, Flammer J, Krieglstein GK, Orzalesi N, Heijl A, Renard JP, Serra LM. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res 2003; 22:769-805. [PMID: 14575724]
47. Kergoat H, Herard ME, Lemay M. RGC sensitivity to mild systemic hypoxia. Invest Ophthalmol Vis Sci 2006; 47:5423-7. [PMID: 17122132]
48. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2:803-11. [PMID: 14526383]
49. Song SJ, Chung H, Yu HG. Inhibitory effect of YC-1, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole, on experimental choroidal neovascularization in rat. Ophthalmic Res 2008; 40:35-40. [PMID: 18032914]
50. DeNiro M, Al-Halafi A, Al-Mohanna FH, Alsmadi O, Al-Mohanna FA. Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygeninduced retinopathy. Mol Pharmacol 2010; 77:348-67. [PMID: 20008515]
51. Kotikoski H, Alajuuma P, Moilanen E, Salmenpera P, Oksala O, Laippala P, Vapaatalo H. Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP. J Ocul Pharmacol Ther 2002; 18:11-23. [PMID: 11858611]
52. Dismuke WM, Sharif NA, Ellis DZ. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel. Invest Ophthalmol Vis Sci 2009; 50:3353-9. [PMID: 19234350]
53. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23:359-69. [PMID: 12482987]